Orogen Therapeutics Selects ORO-110 and ORO-210 Development Candidates for Inflammatory Diseases
Orogen Therapeutics, Inc. (“Orogen” or the “Company”) announced the selection of two development candidates, ORO-110 and ORO-210, as potential next-generation oral small-molecule treatments for a range of inflammatory and immune-mediated diseases. ORO-110 is designed to inhibit interleukin-17 (IL-17), while ORO-210 is a dual-target inhibitor of Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2). Both candidates have completed extensive nonclinical studies demonstrating promising pharmacokinetic and pharmacodynamic characteristics, including nanomolar potency, drug exposure and half-life attributes.
The selection of the two candidates represents a significant milestone for Orogen as it advances its research and development strategy focused on oral therapies for inflammatory disorders. The company intends to develop medicines that could offer alternatives to existing biologic treatments and other therapies for patients whose conditions remain inadequately controlled by current treatment options.
According to Orogen, preclinical findings support the potential of both programs to address important inflammatory pathways while incorporating molecular design features intended to improve the balance between therapeutic activity and safety. ORO-110 has demonstrated inflammation-reducing effects in a preclinical joint inflammation model, while ORO-210 has shown activity against multiple downstream inflammatory cytokines in preclinical models of atopic dermatitis.
The company is now advancing investigational new drug (IND)-enabling studies and current good manufacturing practice (cGMP) manufacturing activities to prepare both candidates for potential clinical development. Orogen is targeting first-in-human dosing for ORO-110 in late 2027, followed by ORO-210 in early 2028.
Although the findings reported to date are based on nonclinical research, the company believes the programs could provide a foundation for developing oral treatments across several dermatological, rheumatological and systemic inflammatory conditions.
ORO-110 Targets IL-17 Signaling to Address Inflammatory Diseases
ORO-110 is an investigational oral small-molecule inhibitor designed to target specific forms of IL-17, a cytokine involved in regulating immune responses and promoting inflammation in several immune-mediated diseases.
IL-17 signaling has an established role in inflammatory conditions affecting the skin, joints and other tissues. Excessive activity in this pathway can contribute to persistent inflammation and disease progression, making it an important target for the development of treatments for disorders such as psoriasis and psoriatic arthritis.
Biologic antibodies targeting IL-17 have become an important treatment option for certain inflammatory diseases. However, oral therapies that effectively modulate the same pathway could offer an alternative administration route for patients and potentially expand treatment choices across different disease settings.
Orogen designed ORO-110 to inhibit the IL-17 AA homodimer and IL-17 AF heterodimer while preserving activity against IL-17 FF. These different IL-17 forms have distinct biological functions, and the company is seeking to develop a treatment that suppresses disease-associated inflammatory signaling while preserving an aspect of immune activity important for mucosal protection.
IL-17 FF contributes to mucosal immunity, which helps defend surfaces such as those lining the mouth and gastrointestinal tract against certain infections. Preserving this activity may be relevant to reducing the risk of opportunistic infections, including candidiasis, which can occur when normal immune defenses are disrupted.
The ability to selectively inhibit IL-17 AA and IL-17 AF while sparing IL-17 FF is therefore a central feature of ORO-110’s intended product profile. Whether this selectivity translates into a meaningful safety advantage in humans will need to be established through further research and clinical testing.
Preclinical Joint Inflammation Results Support Further Development
Orogen reported encouraging results from a preclinical model of joint inflammation in which oral administration of ORO-110 reduced inflammation to a degree comparable to that achieved with a leading anti-IL-17 antibody used as a positive control.
The company also reported mitigation of underlying disease pathology comparable to the antibody control, alongside reductions in downstream cytokine mediators associated with inflammation.
These findings are relevant because inflammatory joint diseases can involve both symptomatic inflammation and structural or tissue-level changes associated with ongoing disease activity. A treatment capable of influencing inflammatory signaling and related pathology could potentially offer broader disease-modifying effects, although the significance of the preclinical observations must be confirmed in clinical studies.
Orogen further reported that ORO-110 reduced inflammation more effectively than a leading competing small-molecule compound in the model, despite being administered at a substantially lower dose.
The comparison provides an early indication of the candidate’s potential potency under the experimental conditions tested. However, differences in dosing, exposure, experimental design and other pharmacological factors must be considered when interpreting comparisons between investigational compounds. These results do not establish clinical superiority over competing treatments.
The company also stated that no adverse events were observed in the preclinical model and that its pilot toxicity studies had not identified safety concerns to date. These findings provide preliminary support for continued development but do not establish the safety of ORO-110 in humans. Additional toxicology studies and clinical evaluations will be required before its risk profile can be adequately characterized.
ORO-210 Designed to Modulate JAK1 and TYK2 Inflammatory Pathways
Orogen’s second development candidate, ORO-210, is a next-generation oral small-molecule inhibitor designed to target JAK1 and TYK2, two enzymes involved in cytokine signaling and the regulation of immune responses.
JAK1 and TYK2 participate in signaling pathways activated by multiple cytokines. These signaling networks influence inflammation, immune cell activity and other processes involved in immune-mediated disease. Modulating these pathways can therefore provide a therapeutic strategy for conditions driven by excessive or dysregulated cytokine activity.
JAK inhibitors are used or investigated across several inflammatory and autoimmune diseases. However, their clinical utility depends on achieving adequate control of disease-associated signaling while managing potential adverse effects associated with interference in immune and hematological pathways.
Orogen is developing ORO-210 with the goal of achieving broad coverage of key inflammatory cytokine mediators while improving the molecular safety profile relative to a leading JAK1/TYK2 small-molecule competitor.
According to the company, preclinical studies in models of atopic dermatitis demonstrated broader coverage of key downstream inflammatory cytokines with a more favorable hematologic and immunologic molecular safety profile than the comparator compound.
The intended product profile also emphasizes enhanced inhibition of downstream cytokines, including interleukin-6 (IL-6), alongside improved selectivity for JAK1 and TYK2 over JAK2.
JAK2 is involved in signaling pathways important for hematopoiesis, the process through which the body produces blood cells. Sparing JAK2 activity may be an important consideration when designing inhibitors intended to reduce inflammation without unnecessarily affecting blood-cell production and related biological functions.
However, molecular selectivity does not by itself establish clinical safety. The degree of pathway inhibition, drug exposure, treatment duration and other pharmacological characteristics can all influence a medicine’s benefit-risk profile. ORO-210 will therefore require additional nonclinical and clinical evaluation to determine whether its intended selectivity translates into meaningful safety advantages.
Atopic Dermatitis Research Highlights ORO-210’s Potential
Atopic dermatitis is a chronic inflammatory skin disease characterized by itching, skin irritation and impaired skin-barrier function. The condition can substantially affect quality of life, particularly when symptoms are persistent or inadequately controlled by available therapies.
Its underlying biology involves multiple immune signaling pathways, making the modulation of inflammatory cytokines an important area of therapeutic research.
Orogen’s preclinical work with ORO-210 in models of atopic dermatitis is intended to evaluate how the candidate influences these pathways and whether its dual JAK1/TYK2 targeting profile can support broad suppression of disease-associated inflammation.
The reported findings suggest that ORO-210 can affect a wider range of key downstream inflammatory cytokines than the leading comparator used in the company’s experiments. Its intended activity against IL-6-related signaling, combined with an emphasis on JAK2 sparing, forms part of the rationale for advancing the candidate.
If these properties are confirmed in subsequent studies, ORO-210 could potentially be investigated in atopic dermatitis and other inflammatory disorders in which JAK1- and TYK2-mediated signaling contributes to disease.
The company has not yet established the candidate’s clinical efficacy, optimal dosage or safety in patients. Its upcoming development work will be important in determining whether the nonclinical findings translate into a therapeutic benefit.
Medical Advisor Highlights the Importance of Selective Inflammatory Pathway Inhibition
Percio Gulko, M.D., Professor of Medicine and former Chief of Rheumatology at the Icahn School of Medicine at Mount Sinai and a medical advisor to Orogen, highlighted the potential role of oral medicines in addressing treatment gaps across inflammatory diseases.
“Oral options represent an important frontier in the treatment of a range of inflammatory disorders where treatment with biologic antibodies has room for improvement. As next-generation oral medicines, ORO-110 and ORO-210 show strong promise in addressing unmet needs in a broad range of patients for whom treatment options to date are suboptimal and where effective oral therapies could expand treatment options and support earlier intervention, subject to clinical evidence,” Gulko said.
He also emphasized the potential importance of the candidates’ distinct molecular characteristics.
“The attributes exhibited by ORO-110 in inhibiting IL-17 AA and AF while avoiding compromise of IL-17 FF activity, and by ORO-210 in more broadly covering the inflammatory cascade mediated via JAK1 and TYK2 signaling, are important in balancing potent efficacy and important safety considerations in immunological disorders,” he added.
The comments reflect the scientific rationale behind the two programs: developing oral medicines that can influence important inflammatory pathways while seeking to preserve biological functions that contribute to normal immune activity.
Oral administration may offer practical advantages for some patients compared with injectable or infused treatments. Nevertheless, the overall value of an oral therapy depends on its effectiveness, safety, tolerability, dosing requirements and suitability for the specific disease being treated.
Potential Development Across Multiple Inflammatory Conditions
Orogen plans to explore ORO-110 and ORO-210 across a range of potential indications based on the pathways each candidate is designed to modulate.
For ORO-110, potential indications include:
- Psoriasis
- Hidradenitis suppurativa
- Psoriatic arthritis
- Axial spondyloarthritis
- Juvenile idiopathic arthritis
These conditions differ in their clinical presentation but can involve IL-17-associated inflammatory processes. Psoriasis primarily affects the skin, while psoriatic arthritis can affect both the skin and joints. Axial spondyloarthritis is an inflammatory rheumatic disease that primarily affects the spine and sacroiliac joints.
Hidradenitis suppurativa is a chronic inflammatory skin condition characterized by painful nodules, abscesses and recurrent lesions. Juvenile idiopathic arthritis encompasses several forms of persistent arthritis that begin during childhood.
The potential relevance of IL-17 inhibition varies across these conditions, and the suitability of ORO-110 for each indication will depend on the results of further research.
For ORO-210, Orogen has identified several potential indications involving inflammatory pathways associated with JAK1 and TYK2 signaling, including:
- Atopic dermatitis
- Sjögren’s disease
- Sclerotic disease
- Sarcoidosis
- Lupus
Sjögren’s disease is an autoimmune condition that can affect moisture-producing glands and other organs. Sarcoidosis is an inflammatory disease characterized by the formation of granulomas in affected tissues. Lupus is a systemic autoimmune disease that can involve the skin, joints, kidneys and other organs.
The company also cited sclerotic disease as a potential area of investigation. The precise indication and development strategy will depend on how the candidate’s pharmacological profile aligns with the biology and treatment needs of the selected patient population.
These indications remain potential future development opportunities rather than established uses for either candidate. Clinical studies will be needed to determine whether the medicines can provide meaningful benefits in any of these conditions.
IND-Enabling Studies Underway Ahead of Planned Clinical Development
Following the selection of ORO-110 and ORO-210 as development candidates, Orogen is advancing IND-enabling studies and cGMP manufacturing activities to prepare for potential first-in-human trials.
IND-enabling work generally includes the nonclinical safety, pharmacology and other studies required to support an application to begin clinical testing. Manufacturing activities are also necessary to produce investigational material under appropriate quality standards for use in clinical studies.
Orogen is targeting first-in-human dosing for ORO-110 in late 2027 and for ORO-210 in early 2028. These timelines are development targets and remain subject to the successful completion of required studies, manufacturing preparations and regulatory processes.
The company stated that both candidates have demonstrated encouraging pharmacokinetic and pharmacodynamic characteristics in nonclinical research, including nanomolar potency, exposure and half-life attributes. These properties will help inform further decisions about dosing strategies and clinical development.
The next stage will be to determine whether the candidates’ preclinical activity and intended molecular selectivity translate into acceptable safety and pharmacological performance in humans. Early clinical studies will typically focus on safety, tolerability, pharmacokinetics and other measures relevant to dose selection and subsequent development.
Orogen Marks a Milestone in Its Drug Development Strategy
Mark Pykett, chief executive officer of Orogen Therapeutics, described the selection of the two development candidates as an important achievement for the company.
“Advancing ORO-110 and ORO-210 to development candidate status are important milestones for Orogen. We are encouraged by the rapid progress the company has made on these programs, culminating in nomination of our first drug candidates in only two years since company inception,” Pykett said. “The rigorous datasets generated to date for our two development candidates provide a strong foundation to advance toward clinical studies.”
The nomination of ORO-110 and ORO-210 establishes the foundation for Orogen’s next phase of development, which will focus on completing the work needed to initiate human testing.
Both programs address inflammatory pathways with established relevance to immune-mediated disease, while incorporating distinct design priorities intended to improve therapeutic selectivity and safety. ORO-110 focuses on selective inhibition of IL-17 AA and IL-17 AF, while ORO-210 is designed to modulate JAK1- and TYK2-mediated signaling with an emphasis on JAK2 sparing.
Although the reported preclinical results are encouraging, clinical trials will ultimately determine whether these characteristics lead to effective and well-tolerated treatments.
As Orogen advances its IND-enabling and manufacturing activities, the planned clinical timelines will represent the next major milestones for the two programs. The company aims to translate its nonclinical findings into investigational oral medicines that could expand treatment options for patients with inflammatory and autoimmune diseases whose needs remain inadequately addressed by existing therapies.
About ORO-110
Orogen’s oral small molecule IL-17 inhibitor development candidate, ORO-110, exhibits potential best-in-class properties with promising in vivo efficacy demonstrated in model systems, including inhibition of the IL-17 AA homodimer and IL-17 AF heterodimer while sparing activity against IL-17 FF, a key component of mucosal immunity the compromise of which can lead to opportunistic infections.
About ORO-210
Orogen’s oral small molecule JAK1/TYK2 dual-target inhibitor development candidate, ORO-210, exhibits next-generation properties that optimize coverage of downstream cytokine-mediators of inflammation while enhancing hematologic/immunologic safety.
About Orogen Therapeutics
Orogen Therapeutics’ mission is to deliver groundbreaking clinical solutions to patients with serious unmet medical needs. Our vision is rooted in redefining small molecule medicines using our innovative drug discovery platform that integrates robust DNA-encoded libraries (DEL) unique and proprietary, target-specific DEL (FocusDEL™) powered by AI to rapidly and effectively develop novel medicines.
We have assembled proprietary on-DNA assets consisting of billions of compounds across nearly 200 libraries and more than 55,000 building blocks, supporting screening efforts that have provided over 1 trillion data points for AI training to date. With a primary focus on immuno-inflammatory diseases, the company is advancing a portfolio of novel oral inhibitors for a range of cytokine targets, including IL-17, JAK1/TYK2, TL1A, FcRn, TNF-alpha, and other targets.